{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T05:02:19Z","timestamp":1777957339075,"version":"3.51.4"},"reference-count":70,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T00:00:00Z","timestamp":1218585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Neuroscience &amp; Therapeutics"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p>Medication nonadherence, especially in psychiatric disorders, has been associated with treatment failure and other negative outcomes. Orally disintegrating formulations have been developed as an alternative to improve medication adherence. This report reviews the properties, efficacy, and safety profile of olanzapine as an orally disintegrating tablet, and explores their association with medication compliance compared with standard oral formulation. Medical literature, published on orally disintegrating formulation of olanzapine identified using Pubmed and EMBASE, was used. Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Studies evaluating the biostability, biodisposability, pharmacokinetics, efficacy, and safety of orally disintegrating olanzapine as treatment of patients with psychiatric disorders were reviewed. Measurement tools included the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impressions\u2010Severity (CGI\u2010S), Simpson\u2010Angus Scale (SAS), Abnormal Involuntary Movement Scale, and Nursing Assessment of Medication Acceptance (NAMA). Orally disintegrating olanzapine, an effective atypical antipsychotic with an acceptable safety profile, can facilitate the burden of treatment on patients and caregivers due to its ease of administration. This is especially important in diseases such as schizophrenia and bipolar disorder, which can be chronic and require long\u2010term treatment.<\/jats:p>","DOI":"10.1111\/j.1755-5949.2008.00053.x","type":"journal-article","created":{"date-parts":[[2008,8,13]],"date-time":"2008-08-13T14:59:17Z","timestamp":1218639557000},"page":"203-214","source":"Crossref","is-referenced-by-count":38,"title":["Olanzapine Orally Disintegrating Tablet: A Review of Efficacy and Compliance"],"prefix":"10.1111","volume":"14","author":[{"given":"Luis","family":"San","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Casillas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Ciudad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inmaculada","family":"Gilaberte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,8,13]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161010-00011"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464230-00006"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519020-00005"},{"key":"e_1_2_9_5_2","volume-title":"Compliance in health care","author":"Haynes RB","year":"1979"},{"key":"e_1_2_9_6_2","unstructured":"National Institute of Health. Research on adherence to interventions for mental disorders. Available athttp:\/\/www.grants.nih.gov\/grants\/guide\/pa\u2010files\/PA\u201003\u2010111.html."},{"key":"e_1_2_9_7_2","first-page":"475","article-title":"Optimizing adherence to pharmaceutical care plans","volume":"40","author":"Nichols\u2010English G","year":"2000","journal-title":"J Am Pharm Assoc"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(97)00467-1"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra050100"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0447.2000.00016.x"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1974.01760170005001"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/21.3.419"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200018020-00002"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.4.692"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01067-8"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.nmd.0000130135.78017.96"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450190043026"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/22.1.69"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.837"},{"key":"e_1_2_9_20_2","first-page":"266","article-title":"Compliance in schizophrenia: Predictive factors, therapeutical considerations and research implications","volume":"28","author":"Misdrahi D","year":"2002","journal-title":"Encephale"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1176\/ps.50.5.667"},{"issue":"5","key":"e_1_2_9_22_2","first-page":"19","article-title":"Relapse prevention and recovery in the treatment of schizophrenia","volume":"67","author":"Schooler NR","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v67n0715"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/23.4.637"},{"issue":"16","key":"e_1_2_9_25_2","first-page":"10","article-title":"Factors influencing compliance in schizophrenia patients","volume":"64","author":"Fleischhacker WW","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370404900504"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-9338(01)00581-8"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v64n0203"},{"key":"e_1_2_9_29_2","unstructured":"U.S. Food and Drug Administration [online]. Available from URL:http:\/\/www.fda.gov\/cder\/dsm\/DRG\/drg00201.htm[Accessed June 30 2008."},{"key":"e_1_2_9_30_2","first-page":"30","article-title":"Orally disintegrating tablets","volume":"7","author":"Deepak K","year":"2004","journal-title":"Tables & Capsules"},{"key":"e_1_2_9_31_2","first-page":"58","article-title":"Orally disintegrating tablets: Taste over speed","volume":"3","author":"Brown D","year":"2001","journal-title":"Drug Deliv Technol"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1998.tb06876.x"},{"key":"e_1_2_9_33_2","unstructured":"DeRocheCC.Consumer preference for orally disintegrating tablets over conventional forms of medication: Evolving methodology for medication intake in dysphagia [lecture].12th Annual Meeting of the Dysphagia Research Society Oct 2\u20134; San Francisco CA .2003."},{"key":"e_1_2_9_34_2","first-page":"1006","article-title":"Compliance in psychiatry: results of a survey of depressed patients using orally disintegrating tablet","volume":"42","author":"Danilevici\u016bte V","year":"2006","journal-title":"Medicina (Kaunas)"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.02.014"},{"issue":"1","key":"e_1_2_9_36_2","first-page":"160","article-title":"Rapid onset of absorption with olanzapine orally disintegrating tablets","volume":"67","author":"Bergstrom RF","year":"2004","journal-title":"Schizophr Res"},{"key":"e_1_2_9_37_2","unstructured":"WitcherJW BergstromRF CerimeleBJ HatcherBL JewellH HemingwayJ RatnasingamLMitchellMI.Pharmacokinetics and bioequivalence of olanzapine rapidly\u2010disintegrating tablets [abstract no. 3431].American Association of Pharmacists Annual Meeting; 1998 Nov 15\u201319; San Francisco ( CA ).1998;Available at URL:http:\/\/www.aapspharmsci.org\/abstracts\/AM_1998\/3431.html[Accessed June 30 2008."},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270005283839"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1177\/070674370204700809"},{"key":"e_1_2_9_40_2","unstructured":"Zyprexa\u2013EU Summary of Product Characteristics. Available from URL:http:\/\/www.emea.europa.eu\/humandocs\/PDFs\/EPAR\/Zyprexa\/H\u2010115\u2010PI\u2010en.pdf[Accessed June 30 2008."},{"key":"e_1_2_9_41_2","unstructured":"Zyprexa Zydis (Olanzapine) Orally Disintegrating Tablets Approved Agreed\u2010Upon Labeling. Available from URL:http:\/\/www.fda.gov\/cder\/foi\/label\/2007\/020592s042s043 021086s022s023 021253s026lbl.pdf[Accessed June 30 2008."},{"key":"e_1_2_9_42_2","first-page":"275","article-title":"The preparation and stability of a liquid olanzapine preparation for oral administration in hospitals","volume":"265","author":"Harvey EJ","year":"2000","journal-title":"Pharm J"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1017\/S1461145703003389"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_2_9_45_2","first-page":"218","volume-title":"Manual for Psychopharmacology","author":"Guy W","year":"1976"},{"issue":"2","key":"e_1_2_9_46_2","first-page":"P01.389","article-title":"Naturalistic use of the orally disintegrating tablet formulation of olanzapine in acute schizophrenic patients: An observational prospective study","volume":"7","author":"Dardennes R","year":"2004","journal-title":"Int J Neuropsychopharmacol"},{"key":"e_1_2_9_47_2","volume-title":"Cochrane Database of Systematic Reviews","author":"Belgamwar RB"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000222516.56143.b1"},{"key":"e_1_2_9_49_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3928\/02793695-20040501-07","article-title":"Orally disintegrating olanzapine: A possible alternative to injection of antipsychotic drugs","volume":"42","author":"Reeves RR","year":"2004","journal-title":"J Psychosoc Nurs Ment Health Serv"},{"key":"e_1_2_9_50_2","first-page":"47","article-title":"Olanzapine orally\u2010disintegrating tablet in severe psychotic agitation: A naturalistic study","volume":"35","author":"Pascual JC","year":"2007","journal-title":"Actas Esp Psiquiatr"},{"key":"e_1_2_9_51_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/PPA.S2300","article-title":"Effectiveness and medication acceptance of olanzapine disintegrating tablets compared to standard olanzapine tablets in acutely treated psychiatric patients","volume":"1","author":"Czekalla J","year":"2007","journal-title":"Patient Preferences and Adherence"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2008.03.004"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2004.14.617"},{"key":"e_1_2_9_54_2","first-page":"232","article-title":"Schizophrenia: Advantages by changeover from olanzapine film\u2010coated tablets to disintegrating tablets","volume":"24","author":"Tiedge UA","year":"2005","journal-title":"Nervenheilkunde"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1951-2"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200629060-00009"},{"key":"e_1_2_9_57_2","first-page":"R284","article-title":"Serotonin contracts the isolated rat pylorus via a 5\u2010HT2\u2010like receptor","volume":"266","author":"Eberle\u2010Wang K","year":"1994","journal-title":"Am J Physiol"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/01213011-200504000-00002"},{"key":"e_1_2_9_59_2","unstructured":"Eli Lilly and Company.Psychopharmacologic Drugs Advisory Committee Briefing Document. Zyprexa\u00ae Olanzapine Pamoate (OP) Depot (Olanzapine Long\u2010Acting Injection) Schizophrenia. Available at:http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008\u20104338b1\u201003\u2010Lilly.pdf. Accessed 19 January 2008."},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.819"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2007.06.004"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1002\/hup.921"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(08)70717-5"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/20.2.297"},{"key":"e_1_2_9_65_2","first-page":"463","volume-title":"Contemporary issues in the treatment of schizophrenia","author":"Weiden PJ","year":"1995"},{"key":"e_1_2_9_66_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199712000-00006"},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.jcp.0000264986.32733.df"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v66n1121e"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2006.09.003"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2354.2006.00735.x"},{"key":"e_1_2_9_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2008.01.904"}],"container-title":["CNS Neuroscience &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1755-5949.2008.00053.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1755-5949.2008.00053.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T16:02:04Z","timestamp":1697040124000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1755-5949.2008.00053.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,13]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1755-5949.2008.00053.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1755-5949.2008.00053.x","archive":["Portico"],"relation":{},"ISSN":["1755-5930","1755-5949"],"issn-type":[{"value":"1755-5930","type":"print"},{"value":"1755-5949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,13]]}}}